Predictive Oncology Inc (NASDAQ:POAI)’s traded shares stood at 1.0 million during the latest session, with the company’s beta value hitting 1.18. At the last check today, the stock’s price was $1.30, to imply an increase of 9.18% or $0.11 in intraday trading. The POAI share’s 52-week high remains $3.76, putting it -189.23% down since that peak but still an impressive 57.69% since price per share fell to its 52-week low of $0.55. The company has a valuation of $8.66M, with an average of 6.41 million shares in intraday trading volume over the past 10 days and average of 1.13 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Predictive Oncology Inc (POAI), translating to a mean rating of 3.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give POAI a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.
Predictive Oncology Inc (NASDAQ:POAI) trade information
After registering a 9.18% upside in the latest session, Predictive Oncology Inc (POAI) has traded red over the past five days. The 5-day price performance for the stock is -3.04%, and 66.59% over 30 days. With these gigs, the year-to-date price performance is 58.44%. Short interest in Predictive Oncology Inc (NASDAQ:POAI) saw shorts transact 0.15 million shares and set a 1.26 days time to cover.
Predictive Oncology Inc (POAI) estimates and forecasts
Looking at statistics comparing Predictive Oncology Inc share performance against respective industry, we note that the company has outperformed competitors. Predictive Oncology Inc (POAI) shares are 11.04% up over the last 6 months, with its year-to-date growth rate higher than industry average at 40.23% against 24.90%.
Revenue forecast for the current quarter as set by 1 analysts is 350k. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 1.5M.
POAI Dividends
Predictive Oncology Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Predictive Oncology Inc (NASDAQ:POAI)’s Major holders
Predictive Oncology Inc insiders hold 2.16% of total outstanding shares, with institutional holders owning 4.01% of the shares at 4.10% float percentage. In total, 4.01% institutions holds shares in the company, led by ADVISORNET FINANCIAL, INC. As of 2024-06-30, the company held over 95.0 shares (or 0.0023% of shares), all amounting to roughly $99.0.
The next major institution holding the largest number of shares is CORNERSTONE PLANNING GROUP LLC with 1.0 shares. As of the market price on 2024-06-30, these shares were worth $1.0.
We also have Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Predictive Oncology Inc (POAI) shares. Going by data provided on Sep 30, 2024, Vanguard Extended Market Index Fund holds roughly 69.88 shares. This is just over 1.05% of the total shares, with a market valuation of $94688.0. Data from the same date shows that the other fund manager holds a little less at 34.66, or 0.52% of the shares, all valued at about 46971.0.
